by angelliu | Mar 5, 2025 | News
Source: Fierce Biotech Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline. Buying Chimerix will give Jazz control of the brain cancer drug...
by angelliu | Dec 16, 2024 | News
Source: FiercePharma The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD). Both products now will be available to a significantly larger patient population as roughly 26 million in the U.S. have...
by angelliu | Sep 18, 2024 | News
Source: FiercePharma With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion,...
by angelliu | Apr 23, 2024 | News
Source: Fierce Biotech Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The acquisition, announced Tuesday, would give Incyte ownership over two budding immunology and inflammation...
by angelliu | Aug 23, 2023 | News
Source: Dermatology Times LEO Pharma announced today its acquisition of Timber Pharmaceuticals, a transaction valued at $36 million.1 Timber Pharmaceuticals has been evaluating the safety and efficacy of its breakthrough therapy, TMB-001, for the treatment of...
